Albany Molecular Research, Inc.

Albany Molecular Research, Inc.

Albany Molecular Research, Inc.

Overview
Date Founded

1998

Headquarters

26 Corporate Circle,Albany, NY 12203

Type of Company

Private

Employees (Worldwide)

1,001 - 5,000

Industries

Other Business & Consulting Services
Holding Companies
Industrial Machinery & Manufacturing
Biotechnology
Pharmaceuticals

Company Description

Albany Molecular Research, Inc. operates as a global contract research and manufacturing organization. It offers drug delivery solutions, drug development, analytical services, API development and manufacturing solutions, and drug product solutions. The company was founded by in and is headquartered in The company was founded by Thomas E. D'Ambra on June 19, 1991 and is headquartered in Albany, NY.

Contact Data
Trying to get in touch with decision makers at Albany Molecular Research, Inc.? Subscribe today to access their professional contact information and receive a one time promotion of free Contact Data credits!
Executives & Employees

Chief Executive Officer

President

President

Chief Financial Officer

Chief Operating Officer

Senior Vice President & General Counsel

Chief Information Officer

Chief Human Resources Officer & Senior Vice President

Vice President

Senior Vice President, Head of Global Operations

Board of Directors

Managing Member at Sterigenics Holdings LLC

Paths to Albany Molecular Research, Inc.
Potential Connections via
Relationship Science
You
Albany Molecular Research, Inc.
Recent Transactions
Details Hidden

LIVIA Corporate Development SE purchases Prime European Therapeuticals SpA from Albany Molecular Research, Inc.

Details Hidden

Lyophilization Services of New England, Inc. purchases Gadea Grupo Farmacéutico SL from Albany Molecular Research, Inc.

Details Hidden

The Carlyle Group LP (Corporate Private Equity), GTCR LLC, Albany Molecular Research, Inc. /Private Group purchase Albany Molecular Research, Inc.

Transaction Advisors
Legal Advisor

Advised onThe Carlyle Group LP (Corporate Private Equity), GTCR LLC, Albany Molecular Research, Inc. /Private Group purchase Albany Molecular Research, Inc.

Accountant

Advised onAlbany Molecular Research, Inc. purchases Organichem Corp.

Escrow Agent

Advised onAlbany Molecular Research, Inc. purchases AMRI Burlington, Inc.

Legal Advisor

Advised onAlbany Molecular Research, Inc. purchases OSO BioPharmaceuticals Manufacturing LLC from Altaris Capital Partners LLC

Legal Advisor

Advised onThe Carlyle Group LP (Corporate Private Equity), GTCR LLC, Albany Molecular Research, Inc. /Private Group purchase Albany Molecular Research, Inc.

Global Chair, Mergers & Acquisitions

Advised onThe Carlyle Group LP (Corporate Private Equity), GTCR LLC, Albany Molecular Research, Inc. /Private Group purchase Albany Molecular Research, Inc.

Advisors & Consultants
Legal Advisor

Partner at Goodwin Procter LLP

Advisor

General Counsel & Corporate Secretary at Moderna, Inc.

Advisor

Director-Education Advancement Board at The University of North Carolina at Charlotte

Clients

General Electric Co. is a technology and financial services company. It operates through the following segments: Power, Renewable Energy, Aviation, Healthcare, and Capital. The Power segment offers technologies, solutions, and services related to energy production, which includes gas and steam turbines, generators, and power generation services. The Renewable Energy segment provides wind turbine platforms, hardware & software, offshore wind turbines, solutions, products & services to hydropower industry, blades for onshore & offshore wind turbines, and high voltage equipment. The Aviation segment provides jet engines & turboprops for commercial airframes, maintenance, component repair, and overhaul services, as well as replacement parts, additive machines & materials, and engineering services. The Healthcare segment provides healthcare technologies in medical imaging, digital solutions, patient monitoring, and diagnostics, drug discovery, biopharmaceutical manufacturing technologies and performance enhancement solutions. The Capital segment leases & finances aircraft, aircraft engines and helicopters, and also provides financial and underwriting solutions. The company was founded by Thomas Alva Edison in 1878 and is headquartered in Boston, MA.

Teva is a global generic pharmaceuticals leader and one of the top 15 pharmaceutical companies in the world. Headquartered in Israel, Teva operates in 60 countries and has 46,000 employees worldwide. Established in 1901, Teva takes great pride in its long tradition of leadership and dedication to excellence

Takeda is a research-based global company with its main focus on pharmaceuticals. As the largest pharmaceutical company in Japan and one of the global leaders of the industry, Takeda is committed to strive towards better health for patients worldwide through leading innovation in medicine. Takeda's ethical drugs are marketed in around 100 countries worldwide.

Key Stats and Financials As of
Market Capitalization
$934M
Total Enterprise Value
Earnings Per Share
Non-Profit Donations & Grants
Political Donations
Investments
Details Hidden

Fluorous Technologies Inc. operates as a chemical technology company which develops and commercializes fluorous products. It uses patented technology to solve synthesis, separation and immobilization problems spanning the entire drug discovery and development process. The firm's products are novel tools that facilitate the synthesis, separation and immobilization of chemical entities and molecular subsets from synthetic and natural mixtures. The company was founded by Dennis P. Curran in June 2000 and is headquartered in Ambridge, PA.

Investors
Details Hidden

GTCR manages a variety of private investment funds that focus primarily on private equity and equity-related investments. Although the main focus of the funds is on private equity investments, the firm may from time to time recommend other types of investments consistent with a respective fund's investment strategy and objectives. GTCR's investments focus primarily on the following sectors: information services and technology, financial services and technology; media & telecommunications; healthcare; and growth business services.

Details Hidden

The Carlyle Group LP (Corporate Private Equity) focuses either on a particular geography (Asia, Europe, Japan, Middle East and North Africa (MENA), South America, Sub-Saharan Africa or the United States) or a particular industry, such as financial services. The firm invests in aerospace, defense & government services, consumer & retail, energy, financial services, healthcare, industrial, real estate, technology & business services, telecommunications & media, and transportation. They provide capital for buyouts and growth capital requirements.

Suppliers
The Broad Institute, Inc. Medical Support Services | Cambridge, MA

The Broad Institute evolved from a decade of informal and successful research collaborations among scientists in the MIT and Harvard communities. In 1990, the Whitehead Institute/MIT Center for Genome Research (WICGR) was founded, and it soon became an international leader in the field of genomics and a flagship of the Human Genome Project. As early as 1995, WICGR scientists recognized the need to bring the power of genomics to the understanding of human disease. It launched pilot projects in genomic medicine, forming an unofficial collaborative network among scientists from across MIT and Harvard who pioneered new approaches to cancer and human genetics. In parallel, Harvard Medical School-based scientists established the Institute of Chemistry and Cell Biology (ICCB) in 1998, to facilitate the pursuit of chemical genetics as an academic discipline and a tool to further understand human biology and disease. In 2002, the ICCB was awarded an Initiative for Chemical Genetics (ICG) grant from the National Cancer Institute, and its successful Investigator-Initiated Screening Program facilitated small molecule screening projects for more than 80 research groups worldwide. These projects demonstrated the power of enabling scientists to collaborate to tackle the major challenges in molecular medicine. It was clear that a new type of formal organization was required — open, collaborative, interdisciplinary, and able to organize projects at any scale. In addition, it was important that the complementary expertise of the genomic scientists and the chemical biologists across MIT and Harvard be brought together in one place to drive the transformation of medicine with molecular knowledge. Discussions in 2002-2003 among Eli and Edythe Broad, MIT, Harvard and its affiliated hospitals, and the Whitehead Institute shaped the vision for this new institute. The extraordinary generosity of Eli and Edythe Broad, through their founding gift of $100 million (later doubled to $200 million) made it possible to formally announce the new institute in June 2003 and to launch it in May 2004. Less than four years after its launch, the Broads gave an unprecedented gift of $400 million in September 2008 to permanently endow the institute, providing long-term sustainability for its unique model of collaborative, inter-institutional research.

Bruker Corp. Hospitals & Patient Services | Billerica, MA

Bruker Corp. engages in the development, manufacture, and distribution of scientific instruments, and analytical and diagnostic solutions that enable customers to explore life and materials at microscopic, molecular, and cellular levels. It operates through the Bruker Scientific Instruments (BSI), and Bruker Energy and Supercon Technologies (BEST) segments. The BSI segment comprises of the Bruker BioSpin Group, the Bruker CALID Group, and the Bruker Nano Group. The BEST segment designs, manufactures, and distributes superconducting materials, primarily metallic low temperature superconductors, for use in magnetic resonance imaging, nuclear magnetic resonance, fusion energy research and other applications. The company was founded by Gunther Laukien in 1961 and is headquartered in Billerica, MA.

HighRes Biosolutions, Inc. Engineering, Construction & Architecture | Beverly, MA

HighRes Biosolutions, Inc. designs and builds robotic systems and laboratory devices used by pharmaceutical and biotech companies and academic research laboratories. It helps scientists accelerate such areas as drug discovery, high-throughput genotyping, siRNA screening, next-generation sequencing sample prep, biorepository science, molecular diagnostics and more. The firm offers modularity, microdock and microcart, acell, nanocell, and accessories. The company was founded by Louis J. Guarracina and Michael J. Nichols in 2004 and is headquartered in Beverly, MA.

This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Albany Molecular Research, Inc.. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Albany Molecular Research, Inc.'s profile does not indicate a business or promotional relationship of any kind between RelSci and Albany Molecular Research, Inc..